Cargando…
The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma
The standard treatment for patients diagnosed with glioblastoma is surgical resection of tumor followed by high dose radiation and chemotherapy with temozolomide. For patients who experience allergic reactions to temozolomide despite desensitization protocols, alternative therapies must be considere...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217712/ https://www.ncbi.nlm.nih.gov/pubmed/30410775 http://dx.doi.org/10.1093/omcr/omy095 |
_version_ | 1783368346033455104 |
---|---|
author | Doyle, Sean P Gurbani, Saumya S Ross, Alexandra S Rosen, Havi Barrett, Charlice Dunn Olson, Jeffrey J Shim, Hyunsuk Shu, Hui-Kuo Sengupta, Soma |
author_facet | Doyle, Sean P Gurbani, Saumya S Ross, Alexandra S Rosen, Havi Barrett, Charlice Dunn Olson, Jeffrey J Shim, Hyunsuk Shu, Hui-Kuo Sengupta, Soma |
author_sort | Doyle, Sean P |
collection | PubMed |
description | The standard treatment for patients diagnosed with glioblastoma is surgical resection of tumor followed by high dose radiation and chemotherapy with temozolomide. For patients who experience allergic reactions to temozolomide despite desensitization protocols, alternative therapies must be considered. In this report, we present such a patient who then received treatment with an epidermal growth factor receptor inhibitor, erlotinib, concurrent with a tumor-treating field device, Optune. Through this combination of a targeted molecular therapy and the Optune device, the patient has been able to achieve stable disease 9 months after completing radiation. |
format | Online Article Text |
id | pubmed-6217712 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62177122018-11-08 The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma Doyle, Sean P Gurbani, Saumya S Ross, Alexandra S Rosen, Havi Barrett, Charlice Dunn Olson, Jeffrey J Shim, Hyunsuk Shu, Hui-Kuo Sengupta, Soma Oxf Med Case Reports Case Report The standard treatment for patients diagnosed with glioblastoma is surgical resection of tumor followed by high dose radiation and chemotherapy with temozolomide. For patients who experience allergic reactions to temozolomide despite desensitization protocols, alternative therapies must be considered. In this report, we present such a patient who then received treatment with an epidermal growth factor receptor inhibitor, erlotinib, concurrent with a tumor-treating field device, Optune. Through this combination of a targeted molecular therapy and the Optune device, the patient has been able to achieve stable disease 9 months after completing radiation. Oxford University Press 2018-11-05 /pmc/articles/PMC6217712/ /pubmed/30410775 http://dx.doi.org/10.1093/omcr/omy095 Text en © The Author(s) 2018. Published by Oxford University Press. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Doyle, Sean P Gurbani, Saumya S Ross, Alexandra S Rosen, Havi Barrett, Charlice Dunn Olson, Jeffrey J Shim, Hyunsuk Shu, Hui-Kuo Sengupta, Soma The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma |
title | The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma |
title_full | The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma |
title_fullStr | The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma |
title_full_unstemmed | The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma |
title_short | The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma |
title_sort | role of erlotinib and the optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217712/ https://www.ncbi.nlm.nih.gov/pubmed/30410775 http://dx.doi.org/10.1093/omcr/omy095 |
work_keys_str_mv | AT doyleseanp theroleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma AT gurbanisaumyas theroleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma AT rossalexandras theroleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma AT rosenhavi theroleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma AT barrettcharlicedunn theroleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma AT olsonjeffreyj theroleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma AT shimhyunsuk theroleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma AT shuhuikuo theroleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma AT senguptasoma theroleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma AT doyleseanp roleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma AT gurbanisaumyas roleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma AT rossalexandras roleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma AT rosenhavi roleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma AT barrettcharlicedunn roleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma AT olsonjeffreyj roleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma AT shimhyunsuk roleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma AT shuhuikuo roleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma AT senguptasoma roleoferlotinibandtheoptunedeviceinapatientwithanepidermalgrowthfactorreceptorviiiamplifiedglioblastoma |